Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Achillion Pharmaceuticals Inc (ACHN) Allied World Assurance Holdings Ltd (AWH) Altra Holdings Inc (AIMC) Ambassadors Group Inc (EPAX) AP Pharma Inc (APPA) Atlas Air Worldwide Holdings Inc (AAWW) Big 5 Sporting Goods Corp (BGFV) Brink's Home Security Holdings Inc (CFL) Bway Holding Co (BWY) Cambrex Corp (CBM) Carrols Restaurant Group Inc (TAST) Cornerstone Therapeutics Inc (CRTX) Cubic Corp (CUB) DSP Group Inc (DSPG) DuPont Fabros Technology Inc (DFT) Electronic Arts Inc (ERTS) Hydrogenics Corp (HYGS) Iconix Brand Group Inc (ICON) ICU Medical Inc (ICUI) Ikanos Communications Inc (IKAN) iPass Inc (IPAS) Kona Grill Inc (KONA) The Laclede Group Inc (LG) Linn Energy LLC (LINE) Macrovision Solutions Corp (MVSN) Meadowbrook Insurance ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Amtrust Financial Services Inc (AFSI) AP Pharma Inc (APPA) Becton Dickinson and Co (BDX) Calavo Growers Inc (CVGW) Cytori Therapeutics Inc (CYTX) Dassault Systemes SA (DASTY) Decode Genetics Inc (DCGN) Dillard's Inc (DDS) Endologix Inc (ELGX) Haemonetics Corp (HAE) Ivanhoe Mines Ltd (IVN) Linktone Ltd (LTON) Navisite Inc (NAVI) Nile Therapeutics Inc (NLTX) Novavax Inc (NVAX) NSTAR (NST) Orchids Paper Products Co (TIS) Papa John's Int'l Inc (PZZA) Provident Energy Trust (PVX) Stericycle Inc (SRCL) TAM SA (TAM) Tucows Inc (TCX) Winner Medical Group Inc (WMDG) View the entire Zacks #1 Rank List.

Zacks Investment Research

A.P. Pharma, Inc. (NASDAQ: APPA) is a specialty pharmaceutical company focused on the development and commercialization of innovative medical treatments utilizing their proprietary polymer-based drug delivery systems.

The company’s proprietary Biochronomer™ technology, featuring bioerodible polymers intended to create controlled-release pharmaceuticals that improve treatments for diseases or health-threatening conditions, is their primary focus as they continue to advance the technology. The company’s lead product candidate is APF530, which is currently in a pivotal Phase III clinical trial for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting, or CINV.

The company has made significant investments in the development of their bioerodible drug delivery technologies, which have produced tangible results. Specifically, A.P. Pharma has developed a broad family of polymers consisting of unique attributes referred to as poly (ortho esters), under the trade name Biochronomer. This technology has been designed for use in drug delivery applications

...

A cancer diagnosis is devastating, and oftentimes the treatment following such diagnosis can be just as mentally and physically debilitating. The majority of patients receiving treatment experience some degree of emesis, or nausea and vomiting, associated with chemotherapy. The prevention and control of emesis is very important for the patient, and chemotherapy patients are typically administered an anti-emetic prior to treatment.

Specialty pharmaceutical company A.P. Pharma Inc. (Nasdaq: APPA) today announced positive results from its pivotal phase III study that compares the efficacy of the company’s lead product, APF530, with Aloxi for the prevention of emesis, also known as chemotherapy-induced nausea and vomiting (CINV).

The phase III trial is based on the participation of 1,395 patients, treated at 103 centers in the United States, Poland and India. The patients were classified according to their level of emetogenic chemotherapy to demonstrate the safety and efficacy of APF530.

According to the

...